《新股消息》嘉和生物(06998.HK)公開超購逾1,246倍 一手中籤率僅3%
未錄得盈利的生物科技股份嘉和生物(06998.HK)公布招股結果,公布發行1.2億股,公開發售錄超購1,246.52倍,凍結資金逾3,625.7億元,國際發售項下初步提呈發售的發售股份已獲超額認購,相當於國際發售項下初步可供認購發售股份總數約33倍。
經重新分配後,香港公開發售股份佔全球發售股份總數上調至約50%。認購一手500股,中籤率僅為3%,要認購180手即9萬股才可穩獲一手。每股上市價定於24元,為上限定價(原每股招股價介乎20.3元至24元),該股將於明日(7日)掛牌上市,聯席保薦人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人為高盛、摩通及Jefferies。
據基石投資協議,基石投資者認購的發售股份數目共5,994萬股,佔緊隨全球發售完成後已發行股本約12.46%。
嘉和生物預計集資淨額26.94億元,其中65%擬分配至主要產品,15%擬用於其管線中其他候選藥物正在進行及計劃進行的臨床試驗、適應症擴展及註冊備案籌備,10%擬用於為其藥物管線擴展提供資金,另外10%則用作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.